Last edition
News about "Dana-Farber Cancer Institute "
Akeso and Inovio Pharmaceuticals Partner to Develop Combination Therapy for Glioblastoma
Akeso and Inovio Pharmaceuticals have entered into a clinical collaboration to evaluate cadonilimab with INO-5412 in glioblastoma. The combination will be studied in the phase-II INSIGhT trial sponsored by Dana-Farber Cancer Institute, building on prior positive data.
Dana-Farber Cancer Institute | 05/03/2026 | By Akanki | 112
Sun Pharma Launches UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma
Sun Pharma has announced the US availability of UNLOXCYT for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation. The updated label includes long-term data supporting durable efficacy and a favourable tolerability profile.
Dana-Farber Cancer Institute | 16/01/2026 | By News Bureau | 108
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy